Drug Trial Radar · NCT05419388
A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma
Last checked: Nov 19, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
93
Actual
Start
Aug 15, 2022
Primary completion
May 1, 2024
Study completion Nov 27, 2025
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics of two dose levels of RO7247669 in participants with unresectable or metastatic melanoma to select the recommended dose for further development.
Conditions
- Melanoma
Interventions
RO7247669Drug
Participants will receive intravenous (IV) RO7247669 Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: From randomization to the first occurrence of progression or death during the treatment period or within 60 days of the last tumor assessment after treatment discontinuation from any cause, whichever occurs first (up to 25 months)
Locations
22 sites in 10 countries. Site status is shown where the registry gives one.
Coffs Harbour Health Campus
Coffs Harbour, New South Wales, Australia
Melanoma Institute Australia
North Sydney, New South Wales, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
One Clinical Research
Nedlands, Western Australia, Australia
Hospital de Clínicas de Porto Alegre X
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Cancer de Barretos
Barretos, São Paulo, Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, São Paulo, Brazil
Hospital Sírio-Libanês
São Paulo, São Paulo, Brazil
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Všeobecná fakultní nemocnice v Praze
Prague, Czechia
District General Hospital of Athens Laiko
Athens, Greece
Auckland City Hospital, Cancer and Blood Research
Auckland, New Zealand
Wellington Hospital
Wellington, New Zealand
Uniwersyteckie Centrum Kliniczne
Gda?sk, Poland
Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie
Warsaw, Poland
Narodny Onkologicky Ustav
Bratislava, Slovakia
POKO Poprad
Poprad, Slovakia
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Clínic i Provincial
Barcelona, Spain
Adana Baskent University Hospital
Adana, Turkey (Türkiye)
Memorial Ankara Hastanesi
Ankara, Turkey (Türkiye)
Medipol Mega Üniversite Hastanesi Göztepe
Istanbul, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.